Gene Translation Laboratory news

7 Aug 2013

Biocat, the organization that coordinates and promotes the biotechnology, biomedical and medical technology sectors in Catalonia, the BioRegion of Catalonia, reports on the European project Nabarsi, which sees the collaboration of the IRB Barcelona spin off Omnia Molecular. The company, developed by Lluís Ribas de Pouplana, ICREA researcher at IRB, will have a key role in this three-year EU project.

Read the news in Biocat (...

18 Jul 2013

The consortium, called NABARSI, will receive 4.1 million euros of funding from the European Commission and is formed by three public research centres and two companies, among these the IRB Barcelona spin-off Omnia Molecular

30 Mar 2012

Lluís Ribas de Pouplana and Eva Novoa's work published today in Cell has features in La Vanguardia. Also, the same newspaper has given the head of the study a green light on the second page.

Link to the news, La Vanguardia (PDF in Spanish; PDF in Catalan)


<p>Researchers Lluís Ribas and Eva Novoa</p>
29 Mar 2012

All living organisms on Earth are divided into three large domains: Archaea, Bacteria and Eukarya, and from the beginning of life –more than 3,000 million years ago -, the genomes of each group have evolved towards distinct structures that have favored their separation. A study led by Lluís Ribas de Pouplana, ICREA researcher at the Institute for Research in Biomedicine (IRB Barcelona) and head of the Gene Translation...

25 Feb 2012

ICREA researcher at IRB Barcelona, Lluís Ribas de Populana, has written the article “De la biología molecular”, dedicated to the memory of the scientist Renato Dulbecco, Nobel Laureate in Medicine 1975, which has been published in the newspaper "La Vanguardia".

Read the article (PDF in Catalan; PDF in Spanish)

25 Jan 2011

In its section Tendencias (trends), the newspaper La Vanguardia devotes an article to the dilemma that researchers sometimes face, namely to patent or set up a company. Spin-offs are one of the options scientists have in order to take advantage of an important finding and the article cites a few success stories. The author highlights Omnia Molecular, founded by Lluís Ribas de Pouplana, Group Leader of the Gene Translation Laboratory at IRB Barcelona, and Cellzome, created by Cayetano Gonzalez, Group Leader of the Cell Division Laboratory at IRB Barcelona, and Luís Serrano, from CRG.

10 Nov 2010

The biotech enterprise Omnia Molecular, which operates from the PCB-Santander Bioincubator at the Barcelona Science Park and was founded by IRB Barcelona researcher Lluís Ribas de Pouplana, has closed funding negotiations headed by “Caixa Capital Risc”, the risk capital section of “la Caixa", worth 2.1M€ . This round of funding, which is supported by the Empresa Nacional de Innovación (ENISA), has also involved the founding partners of Omnia Molecular (Lluís Ribas, Juan Gargallo y Eugeni Roure) and the new managerial team, comprised by Raphael Klingmann, who serves as CEO, and Dariusch Mani.

Omnia Molecular is devoted to the discovery and...